PAMELA MACLAUGHLIN: Open Payments
NPI 1003671967 · BLOOMINGTON, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$256 in 12 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $151 · 2025 $256
Food & beverage: $256
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 2 | $48 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $47 |
| ABBVIE INC. | 2 | $39 |
| Alkermes, Inc. | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| Noven Therapeutics, LLC | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
Products named: COBENFY, CAPLYTA, VRAYLAR, ARISTADA, AUSTEDO XR, Secuado, REXULTI, Qelbree.
Industry payments across IN — which companies pay providers there.
